Durvalumab User Reviews & Ratings
Brand names: Imfinzi
Durvalumab has an average rating of 6.0 out of 10 from a total of 2 reviews on Drugs.com. 50% of reviewers reported a positive experience, while 0% reported a negative experience.
| Condition | Avg. Rating | Reviews | Compare |
|---|---|---|---|
| Non-Small Cell Lung Cancer | 2 reviews for Non-Small Cell Lung Cancer | 57 medications | |
| Add your review | |||
- Anonymous
- Taken for 6 months to 1 year
- April 1, 2024
Imfinzi (durvalumab) for Non-Small Cell Lung Cancer "Had 12 treatments after completion of chemoradiation. Medication was well tolerated with minimal side effects."
Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.
More about durvalumab
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
For Non-Small Cell Lung Cancer "During immunotherapy treatment for one year, I developed constipation, horrible itching all over my body with no relief from creams or any other treatments. Also, it shrunk my thyroid gland, so that I will have to stay on thyroid medicine for the rest of my life. I hope it worked on the cancer. We shall see."